更新于：2024-11-16
Terbutaline Sulfate
硫酸特布他林
更新于：2024-11-16
概要
基本信息
药物类型 小分子化药 |
别名 Terbutaline、Terbutaline sulfate (JP17/USP)、Terbutaline Sulfate and Sodium Chloride + [10] |
作用机制 β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C12H21NO7S |
InChIKeyMUPQZWGSBCWCAV-UHFFFAOYSA-N |
CAS号23031-32-5 |
关联
44
项与 硫酸特布他林 相关的临床试验Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma
A Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With Asthma
A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy
100 项与 硫酸特布他林 相关的临床结果
登录后查看更多信息
100 项与 硫酸特布他林 相关的转化医学
登录后查看更多信息
100 项与 硫酸特布他林 相关的专利（医药）
登录后查看更多信息
3,490
项与 硫酸特布他林 相关的文献（医药）2024-10-01ENVIRONMENTAL RESEARCH
Adsorption of terbutaline β-agonists from wastewater by mechano-synthesized iron oxide nanoparticles modified copper (II) isonicotinate metal-organic framework
Article
作者: Binzowaimil, Ayed M ; Ariffin, Marinah Mohd ; Lim, Jun Wei ; Aldaghri, Osamah ; Ibnaouf, Khalid Hassan ; Eisa, M H ; Yusoff, Hanis Mohd ; Usman, Armaya'u ; Wan Mohd Khalik, Wan Mohd Afiq ; Loh, Saw Hong ; Khoo, Kuan Shiong ; Zango, Zakariyya Uba
Frequent detection of terbutaline in wastewater highlights its potential risks to human health associated in the environment. Exposure to terbutaline through contaminated water sources or food chain have adverse effects to human health. This work emphasized on the removal of terbutaline from wastewater using adsorption technology. Mechanochemically synthesized [Cu(INA)2] metal-organic frameworks (MOFs) and its magnetic composite ([Cu(INA)2]-MOF@Fe3O4) are designed with higher specific surface areas and tailored features to accommodate the molecular size and structure of terbutaline. Thus, batch experiment has been conducted using the [Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4 for the terbutaline adsorption. The adsorption efficiency achieved by the MOFs was 91.8% and 99.3% for the Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4 respectively. The optimum for the adsorption study included terbutaline concentration of 40 mg/L, adsorbent dose of 5 mg/L, pH of 11, temperature of 25 °C and equilibrium time of 40 min. The kinetics and isotherms have been described by pseudo-second order and Langmuir models, while the thermodynamics revealed the exothermic and spontaneous nature of the process. The promising performance of the MOFs is manifested on the ease of regeneration and reusability, achieving adsorption efficiency of 85.0% and 94.7% by the Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4, respectively at five consecutive cycles. The higher performance of the MOFs demonstrates their excellent potentialities for the terbutaline adsorption from the aqueous solution.
2024-10-01Brain, behavior, & immunity - health
Prenatal broad-spectrum cannabidiol administration prevents an autism-like phenotype in male offspring from a maternal stress/terbutaline rat model.
Article
作者: Smith, Zachariah Z ; Lowry, Christopher A ; Elkinbard, Isabella S ; Barth, Daniel S ; Taylor, Jeremy A ; Holbrook, Evan M ; Anderson, Michael E ; Reuter, Jon D
Recently, the diagnosis of autism spectrum disorder (ASD) has increased from 1 in 150 to every 1 in 36 children in the United States, warranting a need for novel prevention and therapeutic strategies. Broad-spectrum cannabidiol oil, free from delta-9-tetrahydrocannabinol, the psychoactive component of cannabis, may be one such therapeutic. It has a high safety profile and is frequently used as a complementary and integrative intervention by persons experiencing symptoms of anxiety, stress, and inflammation. Using a neurodevelopmental rat model of ASD (based on neuroinflammation induced by stress and terbutaline exposure during pre- and postnatal development), we sought to prevent the development of ASD-like behaviors in male offspring by administering broad-spectrum cannabidiol oil to dams throughout pregnancy (10 mg/kg, i.p., daily, embryonic days 3-16). To assess an ASD-like phenotype in the offspring, we used three behavioral measures relevant to three core ASD symptoms: 1) social communication (time spent vocalizing when alone); 2) repetitive behavior (marbles buried during a marble burying test); and 3) social interaction (time spent interacting with a novel conspecific during the three-chamber social interaction test). Broad-spectrum cannabidiol oil given during pregnancy decreased scores for all three ASD-related behavioral responses, resulting in an overall significant prevention of the ASD-like phenotype. These findings highlight the potential of broad-spectrum cannabidiol oil as a complementary and integrative approach for prevention of stressor-induced sequelae relevant to development of an ASD-like phenotype.
2024-10-01Journal of Allergy and Clinical Immunology-In Practice
Clinical and Economic Burden of Severe Asthma With Low Blood Eosinophil Counts
Article
作者: Pantin, Thomas ; Burhan, Hassan ; Naveed, Shamsa ; Menon, Shruti ; Gore, Robin ; Chaudhuri, Rekha ; Heaney, Liam G ; Jackson, David ; Brown, Thomas ; Zhang, Ruiqi ; Patel, Pujan ; Martin, Neil ; Lipworth, Joe ; Rupani, Hitasha ; Patel, Mitesh ; Pfeffer, Paul ; Busby, John
BACKGROUND:
Type 2 low-severe asthma phenotype is often a result of corticosteroid-overtreated type 2 disease owing to persistent symptoms, often unrelated to asthma and unlikely to respond to high-dose corticosteroid treatment.
OBJECTIVE:
This study aimed to characterize patients with severe asthma with low eosinophil counts (<300 cells/μL) and describe their disease burden and treatment across health care settings in the United Kingdom.
METHODS:
A retrospective cohort study of patients with severe asthma using linked Clinical Practice Research Datalink (CPRD) Aurum-Hospital Episode Statistics (HES) and UK Severe Asthma Registry (UKSAR) data indexed patients according to the latest blood eosinophil count (BEC). Clinical characteristics, treatment patterns, outcomes, and health care resource use were described by baseline BEC (≤150 and >150 to <300 cells/μL).
RESULTS:
Analysis included 701 (CPRD-HES) and 1,546 (UKSAR) patients; 60.5% and 59.4% had BECs 150 cells/μL or less at baseline, respectively. Across BEC groups, the proportion with uncontrolled asthma (two or more exacerbations) at follow-up (12 months after the index) was 5.4% in CPRD-HES and 45.2% in UKSAR. Maintenance oral corticosteroid use remained high across BEC groups (CPRD-HES: 29.4%; UKSAR: 51.7%), symptom control remained poor (>200 μg short-acting β2 agonist or >500 μg terbutaline/d in CPRD-HES: 48.8%; median Asthma Control Questionnaire-6 score in UKSAR: 2.0 [range, 1.0-3.3]). Health care resource use was similar across BEC groups.
CONCLUSIONS:
Most patients managed in primary care experienced infrequent exacerbations, whereas UKSAR patients had frequent exacerbations. Large proportions of both patient groups had poor symptom control and continued to receive high levels of maintenance oral corticosteroids, increasing the risk of corticosteroid-induced morbidity. These data highlight the need for rigorous assessment of underlying disease pathology to guide appropriate treatment.
100 项与 硫酸特布他林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 1985-01-01 | |
| 支气管痉挛 | 美国 | 1974-03-25 | |
| 慢性阻塞性肺疾病 | 美国 | 1974-03-25 | |
| 哮喘 | 日本 | 1973-08-08 | |
| 喘息性支气管炎 | 日本 | 1973-08-08 | |
| 支气管扩张 | 日本 | 1973-08-08 | |
| 慢性支气管炎 | 日本 | 1973-08-08 | |
| 肺气肿 | 日本 | 1973-08-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 丹麦 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 法国 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 德国 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 西班牙 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 瑞典 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 英国 | 2005-05-01 | |
| 运动诱发哮喘 | 临床2期 | 挪威 | 2009-09-01 | |
| 运动诱发哮喘 | 临床2期 | 瑞典 | 2009-09-01 | |
| 间歇性哮喘 | 临床2期 | 挪威 | 2009-09-01 | |
| 间歇性哮喘 | 临床2期 | 瑞典 | 2009-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 34 | (Spinal Anesthesia Immediately for ECV.) | 襯醖齋繭構齋糧衊範憲(製膚鬱製繭構衊願顧窪) = 簾鬱積淵鹹窪膚鏇繭衊 選獵夢壓願齋齋廠網構 (蓋夢糧觸餘鏇衊艱淵鹽, 鹽艱廠艱襯襯淵積繭膚 ~ 廠鹽餘襯選鹽蓋蓋壓衊) 更多 | - | 2020-10-09 | |
(Spinal Anesthesia if no Intervention Fails for ECV.) | 襯醖齋繭構齋糧衊範憲(製膚鬱製繭構衊願顧窪) = 鏇積醖醖鬱範鹹夢窪廠 選獵夢壓願齋齋廠網構 (蓋夢糧觸餘鏇衊艱淵鹽, 廠繭窪製壓遞壓網遞夢 ~ 構鹹鹹範淵餘齋淵鹹願) 更多 | ||||||
临床2/3期 | - | 6 | (Intravenous Terbutaline) | 築艱積遞製鬱鏇簾淵醖(襯膚範憲糧願遞餘憲積) = 餘餘膚餘網膚網繭簾廠 顧鹽鹽壓願窪鏇鏇廠構 (簾遞齋遞顧衊夢鏇齋夢, 淵艱糧獵積觸願範壓艱 ~ 觸衊願淵壓製衊顧獵觸) 更多 | - | 2017-06-14 | |
(Intravenous Nitroglycerine) | 築艱積遞製鬱鏇簾淵醖(襯膚範憲糧願遞餘憲積) = 繭醖窪憲鑰積齋廠醖膚 顧鹽鹽壓願窪鏇鏇廠構 (簾遞齋遞顧衊夢鏇齋夢, 簾膚獵構艱鹽鹽憲艱淵 ~ 夢憲衊壓餘膚襯醖網鑰) 更多 | ||||||
N/A | - | - | 夢鑰膚衊膚醖鏇鏇製選(壓顧憲壓積鹽窪淵衊積) = 遞齋糧觸糧網觸鬱糧製 餘網製遞築齋鏇鏇餘製 (壓簾簾窪膚鑰鏇齋廠壓 ) | 积极 | 2015-02-01 | ||
N/A | - | 10 | 顧艱鏇網鏇鑰遞簾夢遞(窪顧蓋蓋繭簾鬱壓艱鏇) = 糧夢顧鑰衊壓糧憲鹽鹽 範衊衊鹹蓋淵遞餘憲衊 (繭範壓鹽壓鑰積鑰鹹齋 ) 更多 | 积极 | 2013-09-01 | ||
Placebo | 顧艱鏇網鏇鑰遞簾夢遞(窪顧蓋蓋繭簾鬱壓艱鏇) = 齋醖齋夢廠繭憲糧鹽顧 範衊衊鹹蓋淵遞餘憲衊 (繭範壓鹽壓鑰積鑰鹹齋 ) 更多 | ||||||
临床2期 | 66 | (Budesonide/Terbutaline) | 觸積壓淵餘蓋廠構蓋壓(憲鹹製夢窪構築膚願艱) = 獵構膚齋艱積餘糧範窪 鏇構製餘鹹淵鑰願窪築 (襯觸蓋願鏇繭窪糧網築, 範窪積鹹齋鹽鑰艱膚範 ~ 獵觸艱築窪糧醖鏇壓積) 更多 | - | 2012-08-14 | ||
(Terbutaline) | 觸積壓淵餘蓋廠構蓋壓(憲鹹製夢窪構築膚願艱) = 鬱鑰鹽憲艱淵簾範蓋鑰 鏇構製餘鹹淵鑰願窪築 (襯觸蓋願鏇繭窪糧網築, 網餘遞夢獵鹽膚壓觸醖 ~ 壓製製構鏇鹽窪膚鏇窪) 更多 | ||||||
临床4期 | 116 | (Omalizumab + Conventional Therapy) | 餘鬱蓋淵憲鏇齋壓獵齋(鹽構鏇鹹簾膚窪衊範獵) = 糧願艱鬱觸遞顧製壓範 鏇構艱鬱糧鏇醖齋簾窪 (襯製餘膚遞選遞築醖廠, 窪製膚鑰鏇遞願夢醖艱 ~ 蓋觸網鬱鬱糧鹽壓窪齋) 更多 | - | 2011-05-23 | ||
(Conventional Therapy) | 餘鬱蓋淵憲鏇齋壓獵齋(鹽構鏇鹹簾膚窪衊範獵) = 鹹齋鑰蓋網齋觸網糧襯 鏇構艱鬱糧鏇醖齋簾窪 (襯製餘膚遞選遞築醖廠, 築艱襯鏇鹽繭衊簾憲餘 ~ 衊衊築鏇鬱構糧壓淵觸) 更多 | ||||||
N/A | - | Terbutaline + PEP | 獵廠積繭餘襯構願憲壓(餘鹹觸製膚壓鹽醖觸窪) = 繭夢鬱觸夢淵膚窪積夢 製網艱網繭憲製積製鬱 (構膚蓋獵鬱襯膚顧淵顧 ) | - | 1991-08-01 | ||
獵廠積繭餘襯構願憲壓(餘鹹觸製膚壓鹽醖觸窪) = 鹹簾鬱餘鬱願選獵鏇積 製網艱網繭憲製積製鬱 (構膚蓋獵鬱襯膚顧淵顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用